Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is).

Abstract

9639 Background: Oral VSP-Is are associated with a significant risk of hypertension (HTN), yet little is known regarding clinical predictors. We describe the association between baseline clinical characteristics, including antihypertensive (antiHTN) therapy, and increased blood pressure (BP) and survival in patients prescribed VSP-Is. Methods: Clinical data was obtained from1120 adults prescribed VSP-Is, identified from electronic medical records (Partners HealthCare, Boston, MA). The primary outcome was worsening HTN (BP≥160/100 mmHg on ≥1 occasion or requiring intensification of antiHTN therapy) in patients with pre-existing HTN, or the development of new HTN in patients with no prior history. Results: The most common cancers wererenal cell (32.2%), hepatocellular (11.6%), GIST (12.5%), and other sarcomas (15.3%). Most patients received sunitinib (52%), sorafenib (25.9%) or pazopanib (18%). Pre-existing HTN was present in 65.4%. The primary BP outcome was identified in 49.9% (median follow-up 4.3 months...